Histology for Interface Stability over Time (HIST) | Apply Online

FAQs: Histology for Interface Stability over Time (HIST) - DARPA (BAA 10-32)

What is the HIST opportunity?

Histology for Interface Stability over Time (HIST) is a DARPA Microsystems Technology Office (MTO) research solicitation under DARPA BAA 10-32. It focuses on understanding why implanted, in vivo neural recording interfaces degrade or fail over time, and how to predict and prevent those failures through rigorous biological tissue assessment paired with engineering and modeling.

What problem is DARPA trying to solve with HIST?

The program targets the practical reliability problem in neurotechnology where chronic (long-term) implanted neural recording interfaces often experience performance degradation or failure. HIST seeks to identify the biological and material mechanisms at the tissue-device boundary that undermine recording stability, so future interfaces can be designed and evaluated more systematically rather than through trial-and-error.

What is the core approach DARPA is encouraging?

DARPA emphasizes "thorough tissue assessment" (histology and related analyses) combined with engineering insight. The intent is to connect what is observed in tissue after implantation (for example, inflammation markers, scarring, cellular changes, structural damage) with measurable interface performance over time, and then use those links to develop predictive tools and reliability indicators.

What kinds of failure mechanisms are relevant to this solicitation?

The solicitation discusses failure mechanisms commonly associated with chronic implants, including inflammatory responses, gliosis and scar formation around electrodes, neuron loss near the recording site, micro-motion induced damage, vascular disruption, material corrosion or delamination, and changes in impedance or signal quality over time.

What does DARPA mean by focusing on the "tissue-device boundary"?

It refers to the interface region where implanted electrode materials and designs physically and biologically interact with living tissue. HIST is aimed at measuring and explaining what changes occur in that region over time and how those changes relate to declining recording performance or outright interface failure.

Does HIST focus only on biology, or also on engineering and materials?

It is explicitly cross-disciplinary, sitting at the intersection of neural engineering, biomaterials, and quantitative histopathology. The goal is not only to describe tissue responses, but to translate biological observations into engineering-relevant understanding, comparative insights across materials/designs, and models that help predict and reduce failure.

What does DARPA mean by moving beyond "trial-and-error" electrode development?

DARPA is seeking research that replaces iterative guessing with evidence-based design. That means using rigorous tissue measurement approaches to identify specific biological and material mechanisms that cause degradation, and then using that knowledge to guide design choices, testing strategies, and methods to improve long-term reliability.

Is DARPA interested in comparing multiple electrode materials and designs?

Yes. The solicitation calls for tissue assessment across "current and potential electrode materials and designs," signaling interest in comparative insight. The emphasis is on understanding why one approach outperforms another and identifying measurable biological signatures that track with better or worse outcomes.

What are the main deliverables or end goals DARPA highlights?

DARPA describes several concrete end goals: (1) predictive models of failure that can forecast interface longevity or performance degradation, (2) robust indicators of interface reliability such as biomarkers or histological features linked to performance, (3) repeatable insertion methodologies to reduce variability from implantation technique, and (4) high-throughput biological test techniques to speed evaluation and iteration cycles.

What are "predictive models of failure" in the context of HIST?

These are models that translate observed biological and mechanical phenomena into forecasts of how long an implanted neural recording interface will remain stable or how it will degrade over time. DARPA indicates these models should ideally guide design decisions and experimental planning.

What counts as "robust indicators of interface reliability" for this program?

The solicitation points to measurable biomarkers, histological features, or other performance-linked metrics that can serve as early warning signs or validated proxies for long-term success. The program emphasis is on indicators grounded in thorough tissue assessment that correlate with interface performance.

Why does DARPA mention repeatable insertion methodologies?

Because implantation technique and insertion mechanics can strongly influence acute injury, chronic biological response, and eventual recording stability. DARPA signals interest in standardized, reproducible insertion protocols that reduce variability and help isolate true device/material effects from surgical technique effects.

What does DARPA mean by "high-throughput biological test techniques"?

It indicates an interest in faster and more scalable assessment workflows that accelerate evaluation cycles. Rather than slow, bespoke analyses that limit iteration speed, DARPA is highlighting approaches that can increase throughput for tissue and interface assessment.

What solicitation is HIST associated with?

HIST is associated with DARPA BAA 10-32, issued through DARPA's Microsystems Technology Office (MTO).

What is Amendment 01 and what does it change?

Amendment 01 is an administrative update that formally replaces the DARPA BAA 10-32 version dated March 3, 2010 with an updated version dated March 4, 2010. Applicants are instructed to rely on the March 4, 2010 BAA text as the controlling document, while the underlying research intent remains the same.

Which BAA version should applicants rely on as the controlling document?

The March 4, 2010 version of DARPA BAA 10-32 is identified as the controlling document due to Amendment 01.

What types of award instruments might DARPA use for this opportunity?

The posting lists multiple possible instruments, including cooperative agreements, grants, "other," procurement contracts, and "other" procurement contracts. This provides DARPA flexibility to structure awards based on the proposed work and the desired level of government involvement.

How is the funding categorized?

The opportunity is categorized as discretionary funding. The funding activity category is Science and Technology and other Research and Development.

What is the CFDA number for this program?

The CFDA number provided is 12.910 (Research and Technology Development).

Is cost sharing or matching required?

No cost sharing or matching requirement is stated in the posting.

Who is eligible to apply?

Eligibility is listed as unrestricted, meaning it is open to any type of entity as allowed by the solicitation details, with the expectation that applicants confirm any specific nuances in the official BAA text and any "Additional Information on Eligibility" section referenced by the announcement.

What are the key submission deadlines?

The posting lists two key deadlines: a proposal abstract due by 11:59 a.m. Eastern Time on April 6, 2010, and a full proposal due by 11:59 a.m. Eastern Time on June 4, 2010.

What time zone applies to the deadlines?

The deadlines are stated in Eastern Time (ET), with submissions due by 11:59 a.m. ET on the specified dates.

When was this opportunity posted and when was it archived?

The posting date is March 3, 2010, with a creation date of March 4, 2010. The archive date is June 21, 2010.

Where can applicants find the full announcement?

The notice points applicants to the MTO solicitations page for the full announcement.

Who is the point of contact for access issues related to the announcement?

The posting provides a contact point through a DARPA program manager and BAA coordinator, identified as Jack Judy, for access issues.

What should a strong proposal emphasize based on the program description?

Based on the description, proposals should align with rigorous post-implant tissue evaluation linked to interface performance, and should aim to produce practical outputs such as predictive failure models, validated reliability indicators, repeatable insertion methods, and/or higher-throughput assessment techniques, potentially with comparative studies across materials and designs.